ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss the topline results of their Lupuzor Phase III trial Q1: Tim, we saw..
Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the topline results of the Lupuzor™ pivotal phase III. Tim provides his perspective on the data issued to the market,..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, announced today the results of its pivotal Phase III trial of Lupuzor™, its lead programme for the potential breakthrough compound..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study,..
ImmuPharma PLC (LON:IMM), specialist drug discovery and development company, has today announced that Tim McCarthy, Chairman, will be presenting at an investor evening hosted by Turner Pope Investments (TPI) Ltd...
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has announced today that, in response to institutional demand, it has completed a fundraise totalling £10 million (before expenses) via..
ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss the completion of their Lupuzor Phase III study Q1: Tim, you provided some..
Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the completion of the Lupuzor™ pivotal phase III study and an initiation of a follow up study. Tim explains the..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the ongoing 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme for the..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed that the last patient has completed dosing within the 52-week, randomised, double-blinded, Phase III clinical trial of..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme..
ImmuPharma PLC (LON:IMM) Non-Executive Chairman Tim McCarthy caught up with DirectorsTalk for an exclusive interview to discuss their interim results, initiating Lupuzor’s regulatory submission, activities for 2017, confidence in announcing..
Immupharma Plc (LON:IMM) Non-Executive Chairman Tim McCarthy talks to DirectorsTalk about the latest interim’s (for the 6 month period ending 30th June 2017), the current status of the Phase III..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced its interim results for the six months ended 30 June 2017 (the “Period”). Key Highlights · Lupuzor™:..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today confirmed a further update on Lupuzor™ its lead programme for the potential breakthrough compound for Lupus, the life..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided the following update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead..
ImmuPharma PLC (LON:IMM) is the topic of conversation when Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview Q1: Now Vadim, you..
Immupharma Plc (LON:IMM) is the topic of conversation when Head of Research at Northland Capital Partners Vadim Alexandre caught up with DirectorsTalk. Vadim provides his thoughts on the key points..
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided an update of its pivotal 52-week, randomised, double-blinded, Phase III clinical trial of Lupuzor™, its lead programme..
